Multiple therapeutic interventions

Phase 2

Multiple therapeutic interventions is one of 2 therapeutic programs targeting HIV (Human Immunodeficiency Virus). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

HIV (human Immunodeficiency Virus)Recruiting

HIV (human Immunodeficiency Virus)Phase 2

Recruiting

Competition

Competitive Landscape

1 competitor in HIV (human Immunodeficiency Virus)

#DrugCompanyPhaseTrials

Sovaldi

Gilead

Approved

1 2

Multiple therapeutic interventions

FFederal University of São Paulo

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

HIV (human Immunodeficiency Virus)

NCT07903441

Clinical

Trials by Indication[1]

HIV (Human Immunodeficiency Virus)1 trial

Phase 2b Clinical Trial Using Multiple Interventions With Distinct Anti-Reservoir Activities In People On Antiretroviral Treatment

Recruiting·FFederal University of São Paulo·Phase 2·NCT07903441·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Multiple therapeutic interventions. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Multiple therapeutic interventions. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Federal University of São Paulo company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: FFederal University of São Paulo

Multiple therapeutic interventions

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

HIV (Human Immunodeficiency Virus)1 trial

References

Drug Info

Quick Facts

Related News